A number of firms have modified their ratings and price targets on shares of Palvella Therapeutics (NASDAQ: PVLA) recently:
- 11/9/2026 – Palvella Therapeutics had its price target raised by Canaccord Genuity Group from $232.00 to $243.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Palvella Therapeutics is now covered by HC Wainwright. They set a “strong-buy” rating on the stock.
- 11/6/2026 – Palvella Therapeutics had its price target raised by Oppenheimer from $210.00 to $232.00. They now have an “outperform” rating on the stock.
- 10/28/2026 – Palvella Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $240.00 price target on the stock.
- 10/20/2026 – Palvella Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
- 10/16/2026 – Palvella Therapeutics was given a new $226.00 price target by Raymond James Financial.
- 10/16/2026 – Palvella Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
- 10/12/2026 – Palvella Therapeutics had its price target lowered by HC Wainwright from $270.00 to $246.00. They now have a “buy” rating on the stock.
- 9/25/2026 – Palvella Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 9/21/2026 – Palvella Therapeutics is now covered by Chardan Capital. They set a “buy” rating and a $240.00 price target on the stock.
Palvella Therapeutics Trading Down 1.4%
Shares of NASDAQ:PVLA opened at $171.62 on Tuesday. Palvella Therapeutics, Inc. has a 12-month low of $72.22 and a 12-month high of $179.95. The company has a market cap of $2.47 billion, a PE ratio of -31.20 and a beta of -0.21. The stock has a 50 day moving average of $143.02 and a 200 day moving average of $128.52.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.08. Equities research analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.
Insider Buying and Selling at Palvella Therapeutics
In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total transaction of $537,313.54. Following the transaction, the chief operating officer owned 2,165 shares in the company, valued at approximately $269,715.70. This represents a 66.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Jenkins sold 7,174 shares of the stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the transaction, the director owned 139,790 shares in the company, valued at approximately $18,223,024.40. This trade represents a 4.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,056 shares of company stock worth $8,756,946 over the last three months. Corporate insiders own 17.20% of the company’s stock.
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania.
Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.
Palvella is led by founder and Chief Executive Officer Wes Kaupinen.
Read More
- Five stocks we like better than Palvella Therapeutics
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
Receive News & Ratings for Palvella Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
